Entering text into the input field will update the search result below

Recro Pharma, Inc. (REPH) CEO Geraldine Henwood on Q2 2018 Results - Earnings Call Transcript

Aug. 07, 2018 3:19 PM ETSocietal CDMO, Inc. (SCTL)1 Comment
SA Transcripts profile picture
SA Transcripts

Recro Pharma, Inc. (REPH) Q2 2018 Earnings Conference Call August 7, 2018 8:00 AM ET


Natalie Wildenradt - IR

Geraldine Henwood - CEO, President & Director

Ryan Lake - CFO


David Amsellem - Piper Jaffray Companies

Kenneth Trbovich - Janney Montgomery Scott

Scott Henry - Roth Capital Partners

Leland Gershell - Oppenheimer & Co.

Patrick Trucchio - Berenberg Capital


Good morning, and welcome to Recro Pharma Second Quarter 2018 Financial Results Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded at the company's request. I would now like to turn the call over to Natalie Wildenradt, Investor Relations. You may begin.

Natalie Wildenradt

Good morning, and thank you for joining us on today's conference call to discuss Recro's second quarter 2018 financial results. This is Natalie Wildenradt, and I am joined today by Gerri Henwood, President and Chief Financial Officer; and Ryan Lake, Chief Financial Officer. Following prepared remarks today by Gerri and Ryan, we will open the call for questions. Earlier this morning we issued a press release detailing our financial and operating results for the three months ended June 30, 2018. The press release is available on the News & Investors page of our website at recropharma.com.

Before we begin our formal comments, I'll remind you that various remarks we make today constitute forward-looking statements pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements related to our financial outlook; our ability to raise capital in terms acceptable to us; our ability to resolve the Complete Response Letter issued by the U.S. Food and Drug Administration on our New Drug Application for IV meloxicam and the timeframe associated with such resolution and our product development plans for other product candidates, including the results and timing of any future, preclinical studies and clinical

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.